Finanzen von Sight Sciences Inc (SGHT)SGHTSight Sciences Inc

Sight Sciences, Inc. (SGHT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Surgical Glaucoma, accounting for 88.6% of total sales, equivalent to $20.71M. Another important revenue stream is Dry Eye. Understanding this composition is critical for investors evaluating how SGHT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Sight Sciences, Inc. maintains a gross margin of 90.96%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -17.05%, while the net margin is -19.01%. These profitability ratios, combined with a Return on Equity (ROE) of -48.42%, provide a clear picture of how effectively SGHT converts its operational activities into shareholder value.

In the context of the broader market, SGHT competes directly with industry leaders such as CLPT and NPCE. With a market capitalization of $448.42M, it holds a significant position in the sector. When comparing efficiency, SGHT's gross margin of 90.96% stands against CLPT's 61.67% and NPCE's 82.83%. Such benchmarking helps identify whether Sight Sciences, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a significant increase in total revenue, reaching 23.39 million USD in Q2 2026, up from 19.66 million USD in Q1 2026. The gross margin is strong at 90.96%, indicating effective cost management despite ongoing losses.